Navigation Links
IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
Date:11/2/2007

ease (SD)) with duration of

response ranging from 7.2 to 29.7 months.

o To date, none of the patients who had an objective response by

RECIST have relapsed.

o The survival rate at 12 months is 67% and 18 patients are still

alive

o Progression Free Survival (PFS) from apheresis is 4.8 months

(95% CI, 3.94-5.72).

-- Assessment of pathological response in 2 patients (1 PR, 1 SD) showed

no residual melanoma.

-- Immune response: 18 out of 29 evaluated patients (62%) showed a

significant increase in TAA-specific cytokine-producing cells.

o The most frequently recognized antigens after vaccination with

UVIDEM were gp100 and MAGE.

-- UVIDEM was well tolerated with only one possibly related serious

adverse event (SAE) reported (age-related macular degeneration).

"The available results of this trial are very encouraging given the difficult-to-treat patient population," said Timothy P. Walbert, president and chief executive officer, IDM Pharma, Inc. "We are confident in the potential of this product to fulfill the unmet medical need and look forward to the completion of our Phase 2 program as well as the initiation of the Phase 3 program."

About UVIDEM

UVIDEM is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. IDM Pharma is responsible for the clinical development, regulatory and manufacturing activities for UVIDEM. Sanofi-aventis has worldwide marketing rights to UVIDEM in melanoma. UVIDEM consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. UVIDEM is produced in IDM Pharma cGMP manufacturing facilities in Irvine, California and in Paris, France.

UVIDEM has been administered to 143 patients in clinical development. Completion of patient enrollment in two Phase 2 clinical trials was previously announced. Thirty-eight
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)FREMONT, Calif., Dec. 4 Vermillion, Inc. (VRML) (Pink Sheets: VRMLQ) announced that on December 3, 2009, it filed its First Amended Plan of Reorganization and related amended Disclosure Statement wit
(Date:12/4/2009)DURHAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company,s Phase II-b, dose escalation, clinical trial in S
(Date:12/4/2009)WASHINGTON, Dec. 4 Chemistry World recently highlighted a new report published by the Pharmaceutical Research and Manufacturers of America ( PhRMA ) that identifies 97 new drugs and vaccines in
Breaking Medicine Technology:Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2Ohio Executive Shares Why Ohio is the Perfect Location for Bioscience Business in National Ad Campaign 14236 1Ohio Executive Shares Why Ohio is the Perfect Location for Bioscience Business in National Ad Campaign 14236 2Ohio Executive Shares Why Ohio is the Perfect Location for Bioscience Business in National Ad Campaign 14236 3CEL SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1 Infected Patients 5038 1CEL SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1 Infected Patients 5038 2CEL SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1 Infected Patients 5038 3CEL SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1 Infected Patients 5038 4Research team finds first evolutionary branching for bilateral animals 10060 1Research team finds first evolutionary branching for bilateral animals 10060 2
...pate and plan for various study outcomes, MEXICO ...(AVAC) today released a new report, Anticipating t...ction from governments, global health,institutions...r initial,results - expected as early as 2009 - fr...tested for HIV prevention, known as PrEP or,pre-ex...
...ctive Drug for Rare Genetic Disorder in,Children--...drug to achieve normal levels of blood sugar in an...gh insulin levels. If this approach,succeeds in hu...hildren,with congenital hyperinsulinism, a rare bu... insulin levels become dangerously high., "There ...
Other Medicine Technology:New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option 2New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option 3New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option 4Treatment Corrects Severe Insulin Imbalance in Animal Studies 2Treatment Corrects Severe Insulin Imbalance in Animal Studies 3
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
(Date:12/4/2009)Rockville, MD "Why is it that men can be bastards and women must wear pearls and smile?" wrote author Lynn Hecht Schafran. The answer, according to an article in the Journal of Vision , may lie in
(Date:12/4/2009)Move a response to pressure from federal regulators to crack down on abuse of opioid medications , , FRIDAY, Dec. 4 (HealthDay News) -- The makers of 24 different prescription painkillers on F
Breaking Medicine News(10 mins):Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Are angry women more like men? 2Health News:Makers of Powerful Painkillers Present Safety Plans 2
...y researchers of St. Thomas’ Hospital, London, had...nit //of the hospital after cardiac surgery can in...e researchers had looked into the medical history ...r patients but who were discharged 48 hours after ...
...ave discovered a newer form of chicken pox vaccine...lled shingles. Shingles (also known as herpe...ashes or blisters on the skin, along with sensatio...ken pox and is caused by the same virus varicella-...
...has shown that nearly half of the patients in the ...experience delirium. Delirium is also one of the m...s. Delirium is a regular occurring condition ...ical costs for the patients and their families. ...
...ers who are constantly exposed to air pollutions o...air they inhale. Inhalation of polluted air o...us in womb. Pollutant particles emitted from the c...by National Institute of Environmental Health Scie...
...ave discovered that the use of the drug sargramost...nts of Crohn’s disease recover totally from their ...for treating cancer patients who are going through...ult to diagnose, as its symptoms are similar to ot...
...id that the problem of inability to read in dyslex...processes as was thought in recent years. Instead,...ems of perception than anything else. Dyslexi...ordination, concentration, perception, memory and ...
Other Medicine News:
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
Medicine Products: